Core Platform

Our Science &
Technology

Pioneering the convergence of 3D bioreactor engineering, targeted exosome modification, and validated disease models to unlock the next generation of regenerative therapeutics.

Explore TechnologyPartner With Us
Technology Platform

Three Pillars of Innovation

Our proprietary technology stack addresses the critical bottlenecks in exosome-based medicine: scalable production, precise targeting, and rigorous validation.

⬡

3D Bioreactor System

Proprietary perfusion-based 3D bioreactor platform achieves 50-100x higher exosome yield compared to traditional 2D culture, with consistent particle quality and scalability from lab to GMP production.

GMP-ReadyScalable
◎

Targeted Exosome Engineering

Surface display technology enables precise tissue and cell-type targeting through engineered ligands, achieving >90% targeting accuracy in validated disease models with minimal off-tissue distribution.

PrecisionEngineered
◈

Disease Model Validation

Comprehensive library of 260+ validated disease models across oncology, neurology, immunology, and metabolic disorders enables rapid preclinical assessment and IND-enabling studies.

260+ ModelsValidated
260+
Disease Models
50+
Patents Filed
50-200nm
Particle Size
9
Partner Hospitals
3D Bioreactor
Bioreactor Platform

Scalable Manufacturing
from Lab to Clinic

Our closed-system 3D bioreactor integrates real-time monitoring of pH, dissolved oxygen, glucose consumption, and lactate production with automated perfusion control, ensuring batch-to-batch consistency critical for regulatory compliance.

  • 10,000L scale-up validated with GMP protocols
  • Real-time particle size and concentration monitoring
  • Automated harvesting and tangential flow filtration
  • Full digital twin integration for process optimization
Exosome Analysis
Quality Control

Rigorous Characterization
& Quality Assurance

Every batch undergoes comprehensive characterization using NTA, TEM, Western blot, and multi-color flow cytometry. Our QC protocol exceeds MISEV2023 guidelines with 47 quality checkpoints per production lot.

  • Nanoparticle Tracking Analysis (NTA) for size distribution
  • Tetraspanin marker panel (CD9, CD63, CD81)
  • Endotoxin levels below 0.1 EU/mL threshold
  • Protein concentration and particle-to-protein ratio QC
Intellectual Property

A Protected Innovation Moat

Our growing IP portfolio covers bioreactor design, surface engineering methods, cargo loading technologies, and therapeutic applications across multiple indications.

50+
Patents Filed
18
Patents Granted
12
PCT Applications
6
Technology Platforms

Ready to Explore Our
Technology Platform?

Discover partnership opportunities for licensing, co-development, or custom manufacturing.

Discuss Partnership